Insider Selling: AcelRx Pharmaceuticals Inc (ACRX) Insider Sells 6,953 Shares of Stock
AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) insider Lawrence G. Hamel sold 6,953 shares of the business’s stock in a transaction that occurred on Monday, September 24th. The shares were sold at an average price of $4.50, for a total transaction of $31,288.50. Following the transaction, the insider now directly owns 24,371 shares of the company’s stock, valued at approximately $109,669.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.
NASDAQ:ACRX traded down $0.10 during mid-day trading on Wednesday, hitting $4.05. 1,637,800 shares of the stock traded hands, compared to its average volume of 603,367. The stock has a market cap of $278.76 million, a P/E ratio of -3.68 and a beta of 2.09. AcelRx Pharmaceuticals Inc has a 12-month low of $1.55 and a 12-month high of $5.75. The company has a current ratio of 4.01, a quick ratio of 3.96 and a debt-to-equity ratio of -0.15.
AcelRx Pharmaceuticals (NASDAQ:ACRX) last issued its quarterly earnings data on Thursday, August 2nd. The specialty pharmaceutical company reported ($0.20) EPS for the quarter, missing the consensus estimate of ($0.19) by ($0.01). The company had revenue of $0.82 million for the quarter, compared to the consensus estimate of $0.93 million. equities analysts forecast that AcelRx Pharmaceuticals Inc will post -0.83 earnings per share for the current fiscal year.
Several equities analysts recently commented on ACRX shares. Zacks Investment Research raised shares of AcelRx Pharmaceuticals from a “hold” rating to a “buy” rating and set a $4.00 price objective for the company in a research note on Tuesday, July 10th. Cantor Fitzgerald started coverage on shares of AcelRx Pharmaceuticals in a research note on Monday, June 11th. They set a “buy” rating and a $6.00 price objective for the company. HC Wainwright reaffirmed a “buy” rating on shares of AcelRx Pharmaceuticals in a research note on Tuesday, August 7th. LADENBURG THALM/SH SH started coverage on shares of AcelRx Pharmaceuticals in a research note on Thursday, August 16th. They set a “buy” rating and a $7.00 price objective for the company. Finally, Oppenheimer reaffirmed a “hold” rating on shares of AcelRx Pharmaceuticals in a research note on Friday, August 3rd. Five equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average price target of $5.21.
About AcelRx Pharmaceuticals
AcelRx Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidate is DSUVIA, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. The company also develops ZALVISO, a pre-programmed and patient-controlled analgesia system that allows hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets to manage their pain.
Receive News & Ratings for AcelRx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AcelRx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.